• 425 Citations
  • 11 h-Index
20082019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Christopher Vinnard is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Meningeal Tuberculosis Medicine & Life Sciences
Tuberculosis Medicine & Life Sciences
HIV Medicine & Life Sciences
Infection Medicine & Life Sciences
Latent Tuberculosis Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Isoniazid Medicine & Life Sciences
Rifampin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2016 2019

Rifampin
HIV
Tuberculosis
Botswana
Research Personnel

Research Output 2008 2019

  • 425 Citations
  • 11 h-Index
  • 30 Article
  • 5 Review article
  • 4 Letter
  • 1 Editorial

Adipose tissue regulates pulmonary pathology during TB infection

Ayyappan, J. P., Ganapathi, U., Lizardo, K., Vinnard, C., Subbian, S., Perlin, D. & Nagajyothi, J., Mar 1 2019, In : mBio. 10, 2, e02771-18.

Research output: Contribution to journalArticle

Open Access
Mycobacterium tuberculosis
Adipose Tissue
Tuberculosis
Pathology
Lung

Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis

Mezochow, A., Thakur, K. T., Zentner, I., Subbian, S., Kagan, L. & Vinnard, C., Jul 1 2019, In : International Journal of Infectious Diseases. 84, p. 15-21 7 p.

Research output: Contribution to journalArticle

Open Access
Meningeal Tuberculosis
Rifampin
Cerebrospinal Fluid
Microbial Sensitivity Tests
Therapeutics
2 Citations (Scopus)

Dual β-lactam combinations highly active against mycobacterium abscessus complex in vitro

Pandey, R., Chen, L., Manca, C., Jenkins, S., Glaser, L., Vinnard, C., Stone, G., Lee, J., Mathema, B., Nuermberger, E. L., Bonomo, R. A. & Kreiswirth, B., Jan 1 2019, In : mBio. 10, 1, e02895-18.

Research output: Contribution to journalArticle

Open Access
Lactams
Ceftazidime
Mycobacterium
Imipenem
Anti-Bacterial Agents

Guidelines-based treatment associated with improved economic outcomes in non-tuberculous mycobacterial lung disease

Marras, T. K., Mirsaeidi, M., Vinnard, C., Chan, E. D., Eagle, G., Zhang, R., Wang, P. & Zhang, Q., Jan 1 2019, In : Journal of Medical Economics.

Research output: Contribution to journalArticle

Open Access
Lung Diseases
Economics
Guidelines
Health Expenditures
Therapeutics

Assessing response to therapy for nontuberculous mycobacterial lung disease: Quo vadis?

Vinnard, C., Mezochow, A., Oakland, H., Klingsberg, R., Hansen-Flaschen, J. & Hamilton, K., Nov 20 2018, In : Frontiers in Microbiology. 9, NOV, 02813.

Research output: Contribution to journalReview article

Lung Diseases
Biomarkers
Therapeutics
Pharmaceutical Preparations
Standard of Care